tbuckley/cabot-search huggingface dataset:
International Directory of Laryngologists and Otologists, containing Names and Addresses of Practitioners engaged in the Study and Practice of Laryngology and Otology.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 344: Cardiac Grafts Engineered From Human Induced Pluripotent Stem Cell Ventricular Pure or Heterogeneous Cardiomyocytes Display Synchronous and Spontaneous Contraction and Reduce Ventricular Tachycardia in Rats with Chronic Heart Failure
Authors: Jordan J Lancaster, Jennifer Koevary, Ikeotunye R Chinyere, Saffie-Alrahman E Mohran, Elizabeth B Juneman, Steven Goldman
Journal: Circulation Research (2017)

Background: Twenty six million people worldwide are diagnosed with chronic heart failure (CHF). With only 5000 heart transplants performed annually, the prognosis for the remaining individuals is poor and new therapeutic options are needed. Previously we have described a cardiac engineered graft comprised of human induced pluripotent stem cell (iPSC) derived cardiomyocytes co-cultured with fibroblasts in a bio-absorbable mesh. Few studies to date have examined comparatively the therapeutic benefits of different cardiac populations. In the present study we engineered grafts generated with either hiPSC derived heterogeneous cardiac myocytes (hetCMs) or ventricular pure myocyte (VMs) populations to compare functional outcomes in a rat model of CHF. Methods: Cardiac grafts were generated with hetCMs or VMs (Axiogenesis) by co-culture into a 3D bioabsorbable mesh with human dermal fibroblasts. The hetCMs contain 60% ventricular, 40% atrial and nodal-like cardiomyocytes. The VMs contain 90% ventricular and 10% atrial cardiomyocytes. Grafts were evaluated in culture out to 6 days. Adult male Sprague-Dawley rats underwent permanent left coronary artery ligation and were randomized to Sham, CHF or graft treatment. Hemodynamic pressure measurements were performed at 6 weeks post-ligation with Millar solid state micromanometer pressure catheters. Ventricular tachycardia (VT) induction studies were performed at study endpoint (3 weeks after implant) to evaluate VT susceptibility using methods developed in the laboratory. Results: Both HetCM and VM generated cardiac grafts displayed synchronous and spontaneous contractions after 48hrs in culture and maintained an average contraction rate of 67±6 (hetCM) and 71±9 (VM) beats per minute (n=10 per group). Implantation of HetCM and VM grafts lowered (p&lt;0.05) EDP 45% and 14% (n=10) and resulted in decreased susceptibility of VT induction 54% and 65%, respectively (n=4). Conclusion: Cardiac grafts engineered with hetCMs or VMs and implanted in a rat CHF model can lower LV EDP in-vivo while decreasing susceptibility of induced VT. This approach raises the possibility that iPSC derived engineered grafts may be used as a treatment for VT in patients with CHF.
Corrigenda
Journal: British Journal of Dermatology (2013)

The authors begin by familiarizing the reader with the dermatopathological features of normal skin and its many appendageal structures.The reader is led chapter by chapter through common and not-so-common tumours of the skin treated by Mohs surgery, along with pitfalls and incidental findings, with a lot of discussion on features that help to discriminate between tumours and normal structures.Importantly, the authors go to great length to describe how to differentiate tumours from one another and, crucially, from normal and benign histology findings.They provide many examples and demonstrate the subtle differentiating features with an extensive and impressive collection of histopathological images.The vast majority of the images, though not quite all, are indeed of the highest qualityno mean feat considering the difficulty of producing perfect frozen-section Mohs slides, then taking digital images and printing them.There are 517 colour images in all.
Factors associated with a malignant or benign course of multiple sclerosis
Authors: V. A. Clark
Journal: JAMA (1982)

Eight hundred thirty-four patients with multiple sclerosis (MS) in King and Pierce Counties, Washington, and in Los Angeles County, California, with symptomatic onset between 1960 and 1969 were followed up for disability status in 1980. A higher proportion of the 375 patients who were not walking or deceased in 1980 had a late age of onset, resided in Los Angeles County, had motor or coordination symptoms at onset, and reported adverse responses to heat exposure and favorable responses to cold exposure, whereas a higher proportion of the 299 patients still walking without aids had early onset age and vision, speech, or sensory symptoms, or all three, at onset. The results suggest (1) that both host factors (age at first manifestation of symptoms and types of symptoms at onset) and environmental factors (place of residence and exposure to heat and cold) are determinants of disease course and (2) that most patients with MS should avoid exposure to heat. (<i>JAMA</i>1982;248:856-860)
Emergency Medicine
Authors: Gary M. Sollars
Journal: JAMA (1981)

Emergency medicine has completed its first full year as a recognized specialty. For the American College of Emergency Physicians (ACEP), 1980 was marked by organizational redefinition, growth, and continued commitment to excellence in the field. Membership in ACEP has increased 10% per year, with a current nationwide census of 10,700. Approved residency programs in emergency medicine now number 55, with a projected graduating class of 309—increasing the total number of residencytrained emergency physicians by 40% in 1981. As a newly recognized specialty organization, the ACEP has added responsibilities to its membership and to the community of medicine. Liaison with specialty societies has begun, with active representation of the ACEP membership in the Council of Medical Specialty Societies and other organizations. Also, the ACEP now represents the emergency physician within the ever-proliferating governmental regulatory bodies. Current issues that the ACEP is addressing include insurance reimbursement parity, regionalization of acute care, and
Bronchial Closure
Authors: G. D. Jack
Journal: Thorax (1965)

A bronchial fistula from a main bronchus is an avoidable complication of lung resection.There are three factors that may contribute to the break- down of a suture line: an inadequate blood supply, tension on the sutures, and infection.Not one of these need occur.The technique of bronchial closure described below makes a fistula from a major bronchus a very rare occurrence. MATERIALTable I lists the type of resection carried out in the 1,100 operations considered in this report.Of TABLE I Type Tuber-Bronchiecof Resection culosis
ELISA technique for quantification of surfactant protein B (SP-B) in bronchoalveolar lavage fluid.
Authors: H J Krämer, R Schmidt, A Günther, G Becker, Y Suzuki, W Seeger
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

Surfactant protein B (SP-B) is one of the essential constituents of the alveolar surfactant system, presenting mainly in the form of SP-B dimer. The measurement of this molecule in biologic samples has been hampered by its extreme hydrophobicity and intimate association with surfactant lipids. We developed a solid-phase, adsorption-based enzyme-linked immunosorbent assay (ELISA) technique for the quantification of SP-B in aqueous solutions. The ELISA employs the hydrophobicity of SP-B for direct binding of this compound to polystyrol immunosorbent plates. Samples are mixed with propanol (1:1 vol/vol) to achieve a homogeneous dispersion of their lipophilic constituents prior to adsorption to the wells. After fluid removal by evaporation, trifluoroethanol is added to optimize SP-B-polystyrol binding, and is then removed, again by evaporation. Subsequent washing procedures (diisopropyl-ether/butanol; Tween 20 in phosphate buffered saline [PBS]) selectively remove phospholipids. Solid phase-bound SP-B is detected by a monoclonal mouse antibody against porcine SP-B, cross-reacting with the apoprotein of human origin. For amplification, a biotinylated anti-mouse antibody and the avidin/biotin-peroxidase technique are used. Steep calibration curves with an excellent reproducibility are obtained for SP-B dimer (range: 0.3125 to 40 ng/well), either introduced directly into the immunosorbent-plate wells or previously admixed with synthetic phospholipid mixtures. SP-B monomer is detected with approximately 10% efficiency as compared with the dimer (wt/wt). Cross-reactivities with human SP-A and SP-C or albumin are negligible. Experiments with spiking of human bronchoalveolar lavage fluid (BAL) samples with different quantities of SP-B dimer revealed virtually complete apoprotein recovery.(ABSTRACT TRUNCATED AT 250 WORDS)
Massachusetts Medical Society
Authors: John Figgis Jewett
Journal: New England Journal of Medicine (1959)

Coronary-Artery DiseaseA forty-year-old gravida 5, para 5, died suddenly six weeks post partum. Prenatally the blood pressure had varied from 120 systolic, 60 diastolic, to 150 systolic, 90 diastolic, and the weight at term had increased from 54.4 to 67.6 kg. (120 to 149 pounds). At term after four hours of easy labor, outlet forceps delivery was achieved under spinal anesthesia, and the post-partum course was marred only by a slight cough on the third day. The patient was discharged on the fifth day and was not heard from again until found dead at home. After her death, the . . .
Myocarditis
Authors: Vernard I. Adams
Journal: JAMA (1990)

<h3>To the Editor.—</h3> Lymphyocytic hypophysitis, occasionally accompanied by adrenalitis, parathyroiditis, thyroiditis, or gastritis, has been strongly associated with the peripartum period. Speculation about the origin recently has focused on autoimmune mechanisms associated with pregnancy.<sup>1</sup>Cardiomyopathy has also been observed as a rare occurrence in the peripartum period. With careful investigation, peripartum cardiomyopathy has often been found to be related to underlying previously quiescent cardiac disease, including myocarditis.<sup>2</sup>Recently, a woman who presented with peripartum cardiomyopathy was found to have both entities. The similarity of the inflammatory infiltrates prompted a literature search for evidence of a common origin. <h3>Report of a Case.—</h3> Eight weeks after the unremarkable delivery of her third child, a 29-year-old woman with asthma and an unconfirmed history of hypertension developed an influenza-like upper respiratory tract infection followed by dyspnea, vomiting, and then congestive heart failure with severe hypotension. She was resuscitated from two cardiac
THE MASTER SURGEON OF DUBLIN
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Correction to the Research Article Titled: “Hematopoietic Stem Cell Gene Therapy for Adenosine Deaminase–Deficient Severe Combined Immunodeficiency Leads to Long-Term Immunological Recovery and Metabolic Correction” by H. B. Gaspar, S. Cooray, K. C. Gilmour, K. L. Parsley, F. Zhang, S. Adams, E. Bjorkegren, J. Bayford, L. Brown, E. G. Davies, P. Veys, L. Fairbanks, V. Bordon, T. Petropoulou, C. Kinnon, A. J. Thrasher
Journal: Science Translational Medicine (2013)
Nouveau traité de médecine.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstracts from the ACNP 34th Annual Meeting, February 15–18, 2007, San Antonio, Texas
Journal: Clinical Nuclear Medicine (2008)

Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Subscribe to eTOC Secondary Logo Journal Logo All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Subscribe Register Login Articles & Issues Current IssuePrevious IssuesPublished Online First Collections ACNM MeetingsCMECommunication in OrganizationCOVID-19Feedback and RewardsFrom the American College of Nuclear MedicineHighly Cited and Frequently Read ArticlesPlanning and Conducting Meetings EffectivelyQuality and Safety in Health CareRecruitment of New PhysiciansTips for Giving a Memorable PresentationTips for LeadersTips for Physicians in Getting the Right Job ACNM ArticlesACNM Website For Authors Submit a ManuscriptInformation for AuthorsLanguage Editing ServicesAuthor Permissions Journal Info About the JournalEditorial BoardAdvertisingOpen AccessSubscription ServicesReprintsRights and Permissions All Articles Images Videos Podcasts Blogs Advanced Search
Ventricular arrhythmias associated with the use of diazepam for cardioversion
Authors: J. S. Barrett
Journal: JAMA (1970)

Two patients undergoing elective cardioversion for atrial fibrillation received diazepam anesthesia intravenously. One patient developed ventricular fibrillation prior to countershock while receiving diazepam and the other developed a short run of ventricular tachycardia following a 100 watt-second shock under diazepam anesthesia. It is thus unlikely that the use of diazepam will allow one to undertake cardioversion without being prepared to cope with all aspects of the occasional catastrophic arrhythmia.
DIABETES MELLITUS.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
Authors: Mario Sznol, Harriet M. Kluger, Margaret K. Callahan, Michael Andrew Postow, Ruth Ann Gordon, Neil Howard Segal, Naiyer A. Rizvi, Alexander M. Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda L. Ralabate, Angel L. Rivera, Stephanie Anne Kronenberg, Blessing Agunwamba, William Feely, Quan Hong, Suba Krishnan, Ashok Kumar Gupta, Jedd D. Wolchok
Journal: Journal of Clinical Oncology (2014)

LBA9003^ Background: We report updated survival and clinical activity in initially enrolled cohorts and activity by BRAF MT status in a phase I trial of concurrent and sequenced NIVO + IPI. Methods: MEL pts (n=53, enrolled 2009-2012, data analysis Dec 2013) with ≤3 prior therapies received IV concurrent NIVO + IPI, Q3Wk × 4 doses, followed by NIVO Q3Wk × 4. At wk 24, NIVO + IPI continued Q12Wk × 8 in pts with disease control and no DLT. Tumor responses were evaluated by WHO and immune-related criteria. Results: Pt characteristics included stage M1c: 55% and prior systemic therapy: 40%. Across doses, 1- and 2-y OS rates were 82% and 75%. Clinical activity was similar to previous reports except CRs rose to 9/53 (17%). Pts with/without tumor BRAF MT (n=36) had similar activity (Table). By wk 36, 42% demonstrated ≥80% tumor reduction. Median duration of response (DOR) was not reached (NR). Of 22 pts with objective response, 14 (64%) had DOR ≥24 wk (range: 25+, 106+). Treatment-related adverse events were as reported previously: grade 3-4, 53% of pts; most common: ↑ lipase and AST (13% ea). Data for sequenced cohorts are shown (Table). Conclusions: Concurrent NIVO + IPI therapy showed encouraging survival and a manageable safety profile in advanced MEL pts. Responses were observed regardless of BRAF MT status and were durable in the majority of pts. Forty additional pts were enrolled (last pt: Nov 2013) on a cohort of NIVO 1 mg/kg + IPI 3 mg/kg Q3Wk × 4 doses, followed by NIVO 3mg/kg Q2Wk (the selected regimen for phase II/III trials). Clinical trial information: NCT01024231. NIVO (mg/kg) + IPI (mg/kg) [n] 1-Y OS rate, % [pts at risk] Median OS, mo ACAR, % ACAR by BRAF MT status,* % [n] Pos Neg Unk 0.3 + 3 [14] 56 [7] 14.8 57 50 [4] 67 [3] 57 [7] 1 + 3 [17] 94 [13] NR 65 50 [2] 50 [6] 78 [9] 3 + 1 [16] 89 [3] NR 81 67 [3] 85 [13] – [0] 3 + 3 [6] 100 [5] NR 83 100 [1] 75 [4] 100 [1] Concurrent [53] 82 [28] 39.7 70 60 [10] 73 [26] 71 [17] Sequenced† [32] Insufficient followup 13.0 44 44 [9] 47 [15] 38 [8] n: no. response-evaluable pts. ACAR: aggregate clinical activity rate = CR+PR+uCR+uPR+irCR+irPR+SD ≥24 wk+ irSD ≥24 wk. *Retrospective analysis. †Pts began NIVO Q2Wk × 48 doses within 4-12 wk after last IPI dose.
More macrolides.
Authors: M J Wood
Journal: BMJ (1991)

year, however, and from these cumulative savings we could begin to afford the new expensive drugs.Placing hospitals on the same footing as their community counterparts, who do not pay value added tax on drugs, would release additional funds.More rational ways of using the nation's resources should be sought, and as a national problem it requires a national solution.The long term benefits of a solution-both financial and in improved working relationships-would handsomely repay any short term infusion of resources.
Enhanced atrioventricular conduction atrial fibrillation after lidocaine administration
Authors: S. T. Sinatra
Journal: JAMA (1977)

LIDOCAINE hydrochloride has been shown to be an effective drug in the treatment of ventricular irritability following myocardial injury and is recommended by some observers for routine prophylactic use in myocardial infarction. Although its efficacy in atrial tachyarrhythmias is limited, some have found it useful, particularly in patients with preexcitation syndromes. Lidocaine, however, like all pharmacologic agents, is not without harmful effects. Accelerated atrioventricular (AV) conduction developed in a patient with atrial fibrillation and left bundle-branch block after a single bolus of lidocaine. <h3>Report of a Case</h3> A 65-year-old man with a past history of myocardial infarction, left bundle-branch block, chronic obstructive pulmonary disease, and recurrent atrial fibrillation was admitted to St Francis Hospital in respiratory insufficiency, which began with shortness of breath two weeks prior to admission. He was being treated with digoxin, quinidine sulfate, and furosemide. On admission, his blood pressure was 170/80 mm Hg; pulse rate, 100
The Tuberculosis Clinic: A Community Health Facility
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal